Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
levofloxacin; imipenem/cilastitin · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| levofloxacin; imipenem/cilastitin | DRUG | - |
Inclusion Criteria: * Diagnosis of hospital-acquired pneumonia as follows: hospitalization \>= 48 but \<= 72 hours, identification of a bacteria commonly found in hospital-acquired infections, absence of pneumonia on initial chest x-ray, normal white blood cell count, and diagnosis other than infec...
Levofloxacin was studied as a treatment for nosocomial pneumonia, which is pneumonia acquired during hospitalization. It was evaluated in a Phase 3 trial comparing it with imipenem/cilastatin in patients with this condition. Levofloxacin is a small molecule anti-infective developed by Johnson & Johnson.
Johnson & Johnson, which trades under the ticker JNJ, is the developer of levofloxacin. The company sponsored the Phase 3 study of levofloxacin in nosocomial pneumonia. Johnson & Johnson is a large healthcare and pharmaceutical company.
Levofloxacin reached Phase 3 development for nosocomial pneumonia. The Phase 3 trial, NCT00236834, has been completed. Levofloxacin is an investigational treatment in this setting and remains in clinical development for the indication studied.
Levofloxacin was evaluated in the Phase 3 trial NCT00236834, titled A Study of the Safety and Effectiveness of Levofloxacin Compared With Imipenem/Cilastatin in Patients With Pneumonia Acquired During Hospitalization. The completed trial enrolled 438 patients aged 18 years and older and compared levofloxacin with imipenem/cilastatin.
The Phase 3 trial NCT00236834 enrolled 438 patients with nosocomial pneumonia. Participants were 18 years of age or older, and both sexes were eligible. The study was randomized and compared levofloxacin with imipenem/cilastatin. The trial has been completed.